22 Psychiatric Medications for Monitoring in Primary Care Medication Warnings, Precautions, and Adverse Events Comments Class: SSRI Fluvoxamine
Used much less than SSRIs in the group of eight
medications for prescribing, probably because it has no
Warnings and Precautions: Similar to other SSRIs
FDA indication for MDD or any anxiety disorder. Still
Adverse Events: Similar to other SSRIs
somewhat popular as a medication for OCD.Monitoring: Same as other SSRIs Citalopram
Escitalopram, one of the SSRIs in the group of
medications for prescribing, is an active metabolite of
Warnings and Precautions: Similar to other SSRIs
citalopram. Escitalopram reportedly has fewer AEs and
Adverse Events: Similar to other SSRIs
less interaction with hepatic metabolic enzymes than
citalopram but is otherwise essentially identical. Citalopram offers no advantage other than price, as
Monitoring: Same as other SSRIs
escitalopram is branded until 2012.Paroxetine
Paroxetine used much less than the SSRIs for
prescribing, probably because of its nonlinear kinetics.
Adult: MDD, OCD, Panic Disorder, Generalized Anxiety
Warnings and Precautions: Similar to other SSRIs
A study of children and adolescents showed doubling
Disorder, Social Anxiety Disorder, Posttraumatic Stress Disorder
Adverse Events: Similar to other SSRIs
the dose of paroxetine from 10 mg/day to 20 mg/day
resulted in a 7-fold increase in blood levels (Findling et
al, 1999). Thus, once metabolic enzymes are saturated, paroxetine levels can increase dramatically with dose
increases and decrease dramatically with dose decreases, sometimes leading to adverse events.
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: SNRI Venlafaxine
Venlafaxine was compared to a second SSRI in children
Warnings and Precautions: Serotonin syndrome,
and adolescents with depression who had not responded
sustained hypertension, mydriasis, discontinuation
to initial treatment with an SSRI (TORDIA study; Brent
symptoms — especially anxiety and insomnia,
et al, 2008). The second SSRI and venlafaxine showed
decreased appetite and weight, height deceleration, comparable efficacy, however, venlafaxine was
activation of mania/hypomania, hyponatremia,
Monitoring: BP, HR, Ht, Wt, suicidality
seizures, increased risk of bleeding events, serum
cholestoral elevation, interstitial lung disease and eosinophilic pneumonia Adverse Events: Asthenia, sweating, nausea, constipation, anorexia, vomiting, somnolence, dry mouth, dizziness, nervousness, anxiety, tremor, blurred vision, abnormal ejaculation/orgasm and impotence in men
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: TRICYCLIC ANTIDEPRESSANTS Nortriptyline
Venlafaxine was compared to a second SSRI in children
Warnings and Precautions: Serotonin syndrome,
and adolescents with depression who had not responded
sustained hypertension, mydriasis, discontinuation
to initial treatment with an SSRI (TORDIA study; Brent
symptoms — especially anxiety and insomnia,
et al, 2008). The second SSRI and venlafaxine showed
decreased appetite and weight, height deceleration
comparable efficacy, however, venlafaxine was
activation of mania/hypomania, hyponatremia,
Monitoring: BP, HR, Ht, Wt, suicidality
seizures, increased risk of bleeding events, serum
cholestoral elevation, interstitial lung disease and eosinophilic pneumonia Adverse Events: Asthenia, sweating, nausea, constipation, anorexia, vomiting, somnolence, dry mouth, dizziness, nervousness, anxiety, tremor, blurred vision, abnormal ejaculation/orgasm and impotence in men Clomipramine Boxed Warnings: Suicidality
The most selectively serotonergic of the TCAs,
Warnings and Precautions: Seizures, orthostatic
clomipramine is used for refractory OCD.
decreases in BP and increases in HR, psychosis,
confusion, mania or hypomania, hepatic enzyme
increases, hematologic changes, hyperthermia, sexual
dysfunction, weight gain, withdrawal symptoms with
Monitoring: Orthostatic BP, HR, blood levels, EKGs to rule out
Adverse Events: Gastrointestinal, including dry mouth, constipation, nausea, dyspepsia, and anorexia; nervous system complaints, including somnolence, tremor, dizziness, nervousness, and myoclonus; genitourinary complaints, including changed libido, ejaculatory failure, impotence, and micturition disorder; and other miscellaneous complaints, including fatigue, sweating, increased appetite, weight gain, and visual changes
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: OTHER ANTIDEPRESSANTS Buproprion
Because of itsstructural similarity to stimulants,
bupropion is sometimes used to treat both depression
Warnings and Precautions: Seizures, hepatotoxicity, agitation and insomnia, psychosis and confusion,
weight gain or loss, allergic reactions, hypertension
Adverse Events: Agitation, dry mouth, insomnia, headache/migraine, nausea/vomiting, constipation,
Monitoring: BP, HR, HT, WT, suicidalityMirtazapine Adverse Events: Somnolence, increased appetite,
Mirtazapine is a tetra-cyclic atypical antidepressant. It is
associated with more somnolence, appetite increase and
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: ANXIOLYTICS Buspirone (azaspirone anxiolytic)
Buspirone is one of the safest and easiest to monitor of
psychiatric medications used to treat children and
Warnings: Co-administration with an MAOI can cause elevated blood pressure
adolescents. However, two large, multisite 6-week
RCTs found no significant differences between
Precautions: Interference with cognitive and motor performance, potential for withdrawal reactions in
buspirone and placebo with regard to the symptoms of
sedative/hypnotic/anxiolytic drug-dependent patients,
generalized anxiety disorder (GAD) following doses
Monitoring: None beyond general health
possible concerns (e.g., a syndrome of restlessness)
recommended for the treatment of GAD in adults.
shortly after initiation of treatment Lorazepam (benzodiazepine)
Primarily because of the possibility of physical and
psychological dependence with prolonged use of
Warnings: Worsening or emergence of depression, suicidality, respiratory depression, interference with
benzodiazepines, lorazepam is generally recommended
cognitive and motor performance, physical and
only for short-term use (days to a few weeks) for
psychological dependence, risk of use in pregnancy,
treatment of acute and severe anxiety following a
trauma or preceding a medical procedure.
Precautions: Paradoxical reactions (i.e., behavioral disinhibition), should not be used with alcohol. Adverse Events: In a sample of about 3500 adult patients treated for anxiety, the most frequent adverse reaction was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%)Clonazepam (benzodiazepine)
Clonazepam is similar to lorazepam, except for its
shorter half-life and once daily dosing.
Warnings: Interference with cognitive and motor performance, suicidality, physical and psychological
dependence, risk of use in pregnancy, withdrawal
Precautions: Worsening of seizures, hypersalivation, should not be used with alcohol
Adverse Events: Somnolence, coordination abnormal, ataxia, depression
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: SECOND GENERATION ANTIPSYCHOTICS Risperidone
Risperidone was the first second generation
antipsychotic (SGA) approved by the FDA (in 1993) for
Adult: Schizophrenia, acute manic or mixed episodes associated
Warnings and Precautions: Neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia and
marketing in the United States. It, along with the other
diabetes mellitus, hyperprolactinemia, orthostatic
SGAs, is most commonly used to treat bipolar spectrum
Child/Adolescent: Schizophrenia (13-17 years), acute manic or
hypotension, leucopenia, neutropenia and
disorders. It is generally effective and safe for short-
mixed episodes (10-17 years), “irritability” associated with
agranulocytosis, potential for cognitive and motor
term use, but there are concerns about adverse effects of
impairment, seizures, dysphagia, priapism, TTP,
long-term use, such as obesity, diabetes, metabolic
Uses: Schizophrenia spectrum disorders, bipolar spectrum
disruption of body temperature regulation, antiemetic
disorders, “irritability” in autism
effect, suicidality Adverse Events: Most common adverse reactions in
Monitoring: HT/WT, glucose, HbA1c, total, LDL, HDL
clinical trials (≥10%): somnolence, increased appetite,
cholesterol, triglycerides, abnormal involuntary movements
fatigue, insomnia, sedation, parkinsonism, akathisia, vomiting, cough, constipation, nasopharyngitis, drooling, rhinorrhea, dry mouth, abdominal pain upper, dizziness, nausea, anxiety, headache, nasal congestion, rhinitis, tremor, rash
Quetiapine Boxed Warnings: Suicidality with antidepressant
Marketed since 1997, quetiapine is associated with more
Adult: Schizophrenia, manic episodes associated with bipolar I or II disorder
Warnings and Precautions: Neuroleptic malignant syndrome, hyperglycemia and diabetes mellitus,
Child/Adolescent: Schizophrenia (13-17 years), manic episodes
hyperlipidemia, weight gain, tardive dyskinesia,
associated with bipolar I disorder (10-17)
orthostatic hypotension, increased blood pressure,
Uses: Schizophrenia & bipolar spectrum disorders
leucopenia, neutropenia and agranulocytosis, cataracts Adverse Events: Most common adverse events in
Monitoring: HT/WT, glucose, HbA1c, total, LDL, HDL
clinical trials in children and adolescents (incidence
cholesterol, triglycerides, abnormal involuntary movements
≥5% and twice placebo): somnolence, dizziness, fatigue, increased appetite, nausea, vomiting, dry mouth, tachycardia, weight increasedAripiprazole Boxed Warnings: Suicidality with antidepressant
Marketed since 2002, aripiprazole has a somewhat
different mechanism of action than other SGAs. It is
Adult: Schizophrenia, acute treatment-manic or mixed episodes
associated with less weight gain than other SGAs except
of bipolar I disorder, maintenance treatment-bipolar I disorder,
Warnings and Precautions: Neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia and
diabetes mellitus, orthostatic hypotension, leucopenia,
Child/Adolescent: Schizophrenia (13-17 yrs), manic or mixed
episodes (10-17 yrs), “irritability” associated with autistic
seizures/convulsions, potential for cognitive and
Adverse Events: Most common adverse reactions in
Uses: Schizophrenia & bipolar spectrum disorders, “irritability”
clinical trials in children and adolescents (incidence
≥5% and twice placebo): somnolence, extrapyramidal
disorder, fatigue, nausea, akathisia, blurred vision,
Monitoring: HT/WT, glucose, HbA1c, total, LDL, HDL
salivary hypersecretion, dizziness , tremor, sedation,
cholesterol, triglycerides, abnormal involuntary movements
Ziprasidone
Marketed since 2001, ziprasidone is associated with less
weight gain than other SGAs. Because of its potential
Adult: Schizophrenia, manic or mixed episodes associated with
Warnings and Precautions: QT interval prolongation, neuroleptic malignant syndrome,
to prolong the QT interval, ECG monitoring is needed.
bipolar I disorder, adjunctive maintenance therapy of bipolar I
tardive dyskinesia, hyperglycemia and diabetes
disorder, agitation in schizophrenic patients (intramuscular
mellitus, rash, orthostatic hypotension, leucopenia,
neutropenia and agranulocytosis, seizures, potential
Uses: Schizophrenia and bipolar spectrum disorders
Adverse Events: Most common adverse reactions in clinical trials (incidence ≥5% and twice placebo):
Monitoring: HT/WT, glucose, HbA1c, total, LDL, HDL
Somnolence, extrapyramidal symptoms, dizziness,
cholesterol, triglycerides, abnormal involuntary movements, QTc akathisia, abnormal vision, asthenia, vomiting
Olanzapine
Marketed since 1996, olanzapine is associated with
more weight gain and related metabolic side effects in
Adult: Schizophrenia, acute treatment of manic or mixed
Warnings and Precautions: Suicide, neuroleptic malignant syndrome, hyperglycemia, hyperlipidemia,
adolescents than other SGAs (Sikich et al 2008; Correll
episodes associated in bipolar I disorder
weight gain, tardive dyskinesia, orthostatic
Child/Adolescent: Schizophrenia (13-17 years), manic or mixed
hypotension, leucopenia, neutropenia and
episodes of bipolar I disorder (13-17 years)
agranulocytosis, seizures, potential for cognitive and
Uses: Schizophrenia & bipolar spectrum disorders
motor impairment, hyperprolactinemia. Adverse Events: Most common adverse reactions in
Monitoring: HT/WT, glucose, HbA1c, total, LDL, HDL
clinical trials of adolescents (≥5% and at least twice
cholesterol, triglycerides, abnormal involuntary movements
that for placebo): sedation, weight increased, headache, increased appetite, dizziness, abdominal pain, pain in extremity, fatigue, dry mouth.
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: FIRST GENERATION ANTIPSYCHOTICS Perphenazine
Perphenazine, a “mid-potency” antipsychotic, was
shown to have comparable effectiveness as the SGAs in
Warnings and Precautions: Tardive dyskinesia,
neuroleptic malignant syndrome, leucopenia,
a large study of adults with schizophrenia (the “CATIE”
neutropenia, agranulocytosis, hyperprolactinemia,
study; Lieberman et al. 2005). In the CATIE study,
Uses: Schizophrenia spectrum disorders, bipolar spectrum
potential for cognitive/motor impairment, impaired
perphenazine was associated with less weight gain and
metabolic side effects than the SGAs.Adverse Events: Acute dystonic reaction,
Monitoring: HT/WT, glucose, HbA1c, cholesterol
extrapyramidal symptoms, withdrawal-emergent
(total/LDL/HDL), triglycerides, liver enzymes, abnormal
dyskinesia, akathisia, somnolence, drowsiness,
autonomic effects (e.g., dry mouth, GI upset, blurry vision)
Haloperidol
Haloperidol, a “high potency” antipsychotic, has been
marketed in the US for over 50 years; it was the most
Adult: Schizophrenia, control of tics in Tourette’s Disorder
Warnings and Precautions: QT interval prolongation, tardive dyskinesia, neuroleptic malignant syndrome,
commonly prescribed antipsychotic in children and
leucopenia, neutropenia and agranulocytosis,
adolescents prior to the introduction of the SGAs in the
hyperprolactinemia, seizures, potential for cognitive
1990s. It is associated with more neurologic adverse
Uses: Schizophrenia spectrum disorders, bipolar spectrum
and motor impairment, impaired liver function
events, but less weight gain and metabolic adverse
Adverse Events: Acute dystonic reaction, extrapyramidal symptoms, withdrawal emergent
Monitoring: HT/WT, glucose, HbA1c, total, LDL, HDL
dyskinesia, akathisia, somnolence, drowsiness,
cholesterol, triglycerides, liver enzymes, abnormal involuntary
various autonomic effects (e.g., dry mouth, GI upset,
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
Medication Warnings, Precautions, and Adverse Events Comments Class: MOOD STABILIZERS Lithium (Element of the alkali-metal group) Boxed Warnings: Toxicity closely related to serum
Introduced in the US in the early 1960s, it was the
levels; can occur close to therapeutic dose levels
original mood stablilizer. It has clear, documented
Manic episodes of bipolar disorder, maintenance treatment
evidence of effectiveness for acute and maintenance
Warnings: Very high risk of toxicity: significant cardiovascular or renal disease, severe debilitation,
treatment for mania and bipolar disorder in adults.
Child/Adolescent: Appears to have “grandfathered” indication
dehydration, sodium depletion, taking diuretics or
There has been no well-powered study for mania in
angiotensin converting enzyme (ACE) inhibitors.
children and adolescents, in large part because of the
Uses: Acute mania in bipolar disorder, also maintenance therapy
Chronic use may lower renal concentrating ability,
ethical and practical difficulties with doing placebo-
can present as nephrogenic diabetes insipidus, with
controlled studies. Evidence is mixed from several
Monitoring: Pregnancy testing, serum levels, ECG, CBC, thyroid
polyuria/polydipsia. Encephalopathic syndrome (i.e.,
smaller studies (Geller et al 1998, Kafantaris et al 2004,
weakness, lethargy, fever, tremulousness and
Kowatch et al 2007). Its indication for 12-17 year olds
confusion, leukocytosis, extrapyramidal symptoms,
is not based on rigorous safety and efficacy data.
elevated serum enzymes, BUN and FBS) may occur
Unpopular with children and adolescents because of
with lithium and a neuroleptic, often haloperidol.
common side effects and the need for repeated
Precautions: Hypothyroidism, impaired mental or
venipunctures for serum level monitoring.
physical abilities, any concomitant medications, i.e., diuretics, ACE inhibitors, carbamazepine, fluoxetine Adverse Events: Mild <1.5 mEq/L; Mild/moderate 1.5-2.5 mEq/L; Moderate/severe ≥2.0 mEq/L. <2.0 mEq/L: early signs of toxicity-diarrhea, vomiting, drowsiness, muscular weakness and lack of coordination; At higher levels: giddiness, ataxia, blurred vision, tinnitus, large output of dilute urine; At >3.0 mEq/L: complex clinically with multiple organs and organ systems
Valproic Acid (anticonvulsant) Boxed Warnings: Hepatotoxicity — can be fatal,
Valproic acid to treat mania in adults is supported by
usually in first 6 months of use in children <2 years.
substantial data. A yet unpublished, 24-week RCT had
Adult: Acute treatment of manic episodes associated with bipolar Teratogenic, includes neural tube defects, e.g., spina
response rates of divalproex = 54%, lithium = 42% and
disorder, therapy of complex partial seizures and simple and
bifida. Pancreatitis — can be fatal, hemorrhagic cases placebo = 29% (Kowatch et al 2007). A recent,
complex absence seizures, prophylaxis of migraine headaches
industry-funded, multisite RCT in youth with mania and
Child/Adolescent: None for psychiatric disorders
Warnings and Precautions: Suicidality, thrombocytopenia, multiorgan hypersensitivity
bipolar disorder did not show efficacy of valproic acid
reaction, hypothermia, hyperammonemia, CNS
versus placebo (Wagner et al 2009). The usefulness of
“depression” when used with sedating drugs. Hepatic
valproic acid in child psychiatric disorders is debatable
Monitoring: Pregnancy testing, serum levels, CBC, liver function
enzyme induction can affect many other drug levels
given that the only published RCT of valproate for
Adverse Events: Most common adverse reactions in
clinical trials of mania (incidence ≥5% & >5% above placebo): Nausea, vomiting, somnolence, dizzinessCarbamazepine/Oxycarbamazepine (anticonvulsant) Boxed Warnings: Serious, potentially fatal
Carbamazepine was introduced in the US in 1968 for
dermatologic reactions (toxic epidermal necrolysis
treatment of seizures but has well-documented efficacy
and Stevens-Johnson Syndrome), aplastic anemia,
for treating mania in bipolar disorder in adults. There
Child/Adolescent: None for psychiatric disorders
have been no RCTs in children and adolescents with
Warnings and Precautions: Suicidality. Can affect
bipolar disorder. The medication can be difficult to
manage because of its numerous drug interactions
Monitoring: CBC with platelets, serum levels, Chinese ancestry-
test for HLA-B*1502 before starting treatment
Adverse Events: The most frequently observed
adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomitingLamotrigine (anticonvulsant) Box Warnings: Life-threatening rash (e.g., Stevens-
There are no RCTs of lamotrigine in children and
Johnson syndrome), toxic epidermal necrolysis,
Adult: Maintenance treatment of bipolar disorder, including
higher risk in: youth than adults, use with valproate,
exceed recommended initial dose/dose escalation.
May be benign — unable to predict if serious rash,
stop at first sign unless clearly not drug-related. Warnings and Precautions: Hypersensitivity reaction,
Monitoring: CBC and liver function studies
suicidality, acute multiorgan failure, blood dyscrasias,
clinicial worsening and emergence of new symptoms in bipolar disorder, aseptic meningitis, medication errors because of name similarities to other drugs Adverse Events: >5% in adult bipolar studies: nausea, insomnia, somnolence, back/abdominal pain, fatigue, rhinitis, xerostomia
Compiled by Mark A. Riddle, MD, and Susan dosReis, PhD, Center for Mental Health Services in Pediatric Primary Care, Johns Hopkins School of Public Health. Updated July 2011.
What to expect after your SuperPATH hip replacementWhile the experiences of patients vary somewhat, there are a number of things that patients share in common after having a hip replacement via the SuperPATH approach. Please remember that there is someone available 24 hours a day to answer any questions you may have after surgery. Please call 952-993-3230 with any concerns. Walking AidesYou shou